Jarrod Winters United States

DermSpectra has developed an innovative high resolution full body imaging system designed to aid early detection of skin cancers and diseases, and revolutionize medical documentation.  The DermSpectra Automated Total Body Digital Skin Imaging (DSI) System fills a key technology gap in medical imaging, empowers physicians with an objective tool to accurately and efficiently detect and monitor skin and body changes over time and raises the bar for patient care.

Main Sector
Medtech Phase of Development
Technology Overview

The DermSpectra Total Body Digital Skin Imaging System is a proprietary solution that delivers patented high-resolution imaging, secure storage, and immediate viewing capabilities. With the most advanced level of precision in the market, DermSpectra sets the industry standard (definition, timing, lighting, image quality, data formats, secure storage, and interfaces) in digital skin imaging for dermatologists, plastic surgeons, cancer centers, clinical trials, general practitioners, and telemedicine services. The DermSpectra Total Body Digital Skin Imaging System solution strives to improve early detection of melanomas, skin cancers and treatment outcomes for patients and physicians by providing skin images that enable a comprehensive view and comparison of skin lesions and body changes over time.

Dermspectra LLC
Chief Operating Officer 

Neil Wyant

Everett Partners is the venture investing arm of an Akron Ohio based single family office.  The firm owns and manages an incubator in Israel and invests in companies in the life sciences space with a focus on technolog enabled, non-invasive medical devices.

Sector Interest
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Everett Partners
Managing Director 

Weixin Xu

BVCF
Principal 

Davis Yang

BVCF
Managing Partner 

Jean Yao United States

Jean Yao, PhD, with 20+ years of extended experience in the areas of biology, medical research, and medical industry, has held various positions at Mayo Clinic and University of Minnesota. She funded Med Qiao Group LLC as for the Bridge between US and China in life science. Med Qiao provides business consulting services that include investment funding, market analysis, intellectual property protection, clinical trial arrangement, product approval application, China branch or division establishment as well as marketing, promotion, distribution and onsite manufacturing of medical products.

Med Qiao Group LLC
Managing Partner 

Nadim Yared

CVRx, Inc.
President and Chief Executive Officer 

Mikihiro Yasuda

DeNa
Partner, Strategic Investment 

Charles Yeomans

Trigemina
President 

Simon Yi United States

PhysioCue is a medical device company that has developed an anti-hypertension medical device, clinically shown to immediately reduce the high blood pressure of hypertensive patients. This device is non-invasive and works by controlled cold therapy with the carotid artery baroreceptor reflex. Unlike drug treatments, our PhysioCue therapy device is efficient, safe, easy to use, non-invasive, and has none of the side effects associated with anti-hypertensive drugs. We also develop mobile Health device.

PhysioCue’s Mechanism of Action is the body’s natural baroreflexive system which provides important monitoring and feedback for blood flow throughout the body. It activates baroreceptors in the wall of the carotid artery which stimulate the afferent and efferent pathways of the automatic nervous system. To lower excessive blood pressure the brain responds by modulating efferent pathways, which relaxes the blood vessels, slows the heart rate and reduces fluid in the body. These actions reduce the afterload on the heart by decreasing arterial resistance, which improves the heart’s ability to pump blood to the tissues. The increase in parasympathetic tone and decrease in sympathetic drive results in the restoration of sympathetic-vagal balance which reduces excessive blood pressure and improves cardiac structure and function.

PhysioCue’s video has been published on YouTube http://youtu.be/A1bMjg5a3MY ,

Year Founded
2013
Main Sector
Indication
Biotech Phase of Development
Medtech Phase of Development
Technology Overview
anti-hypertension medical device
Supporting Metrics or Evidence
baroreflexive system
Current Financing Needs
$3M
Current Investors
Danen Ventures, TEEC Angels, Nextplay Ventures
IP Status
Issued IPs
PhysioCue
LinkedIn logo CEO 
BIO

Mr. Simon is a Silicon Valley veteran with nearly 20 years of experience in start-up manufacturing in the lubrication, bio sensory, and medical device industries. Most recently, Simon is a founder and CEO of PhysioCue, consumer medical device company at Silicon Valley and a co-founder of VORA OIL, a chemical engineering company dedicated to bringing highest performing industrial lubricants to the market, without causing disturbance to the environment and he is a founder and CEO at AcuTend, a medical device company that helps hypertension patients lower their high blood pressure to safe levels without the use of drugs. Simon was the Vice President of Technology and a co-founder at NeuroSky, which focused on the manufacturing and R&D of bio sensor for EEG, and EOG signals. He was a vice president at OpticLayer which focused on the manufacture optical filters, wires, and wireless combine telecommunication filter system with fully integrated electronics. Simon enjoyed and has hands on experienced in building revenue companies from scratch. Simon’s career began at HOYA Corporation, U.S.A.

Nathan Yoganathan

Kalgene Pharmaceuticals
CEO